Predict your next investment

HEALTHCARE | Biotechnology
cellectivedx.com

See what CB Insights has to offer

Founded Year

2005

Stage

Unattributed VC - II | Alive

Total Raised

$24.72M

Last Raised

$5M | 13 yrs ago

About CELLective Dx Corporation

CELLective Dx is an early-stage company developing a new generation of diagnostic tools for cancer based on analysis of CTCs directly from a patient's blood. Our novel proprietary technologies combine microfluidics, flow dynamics, cell biology, molecular biology, biochemistry, and surface chemistry to capture and analyze rare CTCs in blood more rapidly and effectively than other current technologies. CELLective Dx is developing simple, rapid, blood-based cancer tests that will provide physicians and patients with accurate and individualized clinical information on disease status, treatment selection, and treatment response that will dramatically improve the clinical management of cancer.

CELLective Dx Corporation Headquarter Location

265 North Whisman Road

Mountain View, California, 94043,

United States

650-938-9800

Latest CELLective Dx Corporation News

Biological Dynamics Appoints Paul Billings MD PhD to Board of Directors

Nov 10, 2015

SHIRE PLC - Shire Appoints Sara Mathew to Board of Directors Dr. Billings is a nationally recognized expert in genomics and molecular medicine. He is renowned for his contribution to improving patient care by bringing in new genomic technologies to the clinic. He currently serves as an Executive-in-Residence at Janssen Diagnostics, a division of Johnson & Johnson Inc., and is the Medical Director of the IMPACT Cancer Care Program at Thermo Fisher Scientific (TFS). Dr. Billings brings to Biological Dynamics a blend of business, research, regulatory, and health care experiences. Dr. Billings has served on the Scientific Advisory Board of the FDA and the Genomic Medicine Advisory Committee at the Department of VA. He has also held academic appointments at Harvard University, U.C. San Francisco, Stanford University, and U.C. Berkeley, and has served as a physician at a number of leading medical centers. Dr. Billings’ business background ranges from guiding clinical strategies as a Chief Medical Officer of Life Technologies Inc. - and then of the Genetic Sciences Division of TFS - to fostering the success of several early stage genetic and diagnostic companies. Dr. Billings has founded and led GeneSage Inc., Omicia Inc., and CELLective Dx Corporation. He is currently a Board Director of Trovagene Inc. and Renova Health Inc., both publicly traded personalized medicine companies. “Biological Dynamics is bringing to market a technology that could potentially revolutionize how we look at individual response to cancer treatments,” said Dr. Billings. “Treatment response is at the crux of precision medicine. It is a key input into treatment plans; adding clarity to evaluating individual responses will drive better plans, and ultimately, better patient outcomes.” “We are fortunate to have Dr. Billings bring his extensive expertise in bringing promising technologies to clinical markets to our Board,” says Raj Krishnan, CEO of Biological Dynamics. “With the new funding fueling our regulatory and commercialization efforts for our first oncology product, TR(ACE)™ , Dr. Billings’ guidance in navigating the ecosystem of patient care will be essential to our success.” About Biological Dynamics Biological Dynamics is a private molecular diagnostics company located in San Diego. Our proprietary technology offers a novel, fast, and cost-effective lab-on-chip ACE platform that isolates nanoparticles from high conductance physiological solutions. Blood based nanoparticles have been shown to be clinically relevant in a number of therapeutic areas, including oncology, transplant health, and reproductive medicine. The company’s first product, the TR(ACE)™ assay, will utilize the platform for monitoring treatment response in oncology. TR(ACE)™ has not been cleared or approved by the U.S. Food and Drug Administration or any foreign regulatory agency. For more information, please visit  www.biologicaldynamics.com and follow on Twitter @BiodynSD View source version on businesswire.com: http://www.businesswire.com/news/home/20151110005321/en/ Biological Dynamics Inc.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CELLective Dx Corporation

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CELLective Dx Corporation is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CELLective Dx Corporation Patents

CELLective Dx Corporation has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/25/2008

8/30/2011

Transcription factors, Cell biology, Clusters of differentiation, Biotechnology

Grant

Application Date

2/25/2008

Grant Date

8/30/2011

Title

Related Topics

Transcription factors, Cell biology, Clusters of differentiation, Biotechnology

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.